Brussels, 16/12/2005 (Agence Europe) - A review by the European Medicines Agency (EMEA) of new safety information for the flagship flu jab Tamiflu (produced by Swiss pharmaceuticals company Roche) has concluded that no change to the product safety information is required. In November, a report from Japan on the suicides of several teenagers taking oseltamivir (the scientific name for Tamiflu) led the US FDA and the EMEA to request further information from Roche. The EU's Committee for...